Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AZN
AZN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AZN News
IMFINZI Approved for High-Risk Bladder Cancer Treatment
1d ago
Newsfilter
Regulatory Approvals and Collaborations in Biotech Sector
1d ago
NASDAQ.COM
AstraZeneca's IMFINZI Approved by FDA for Bladder Cancer Treatment
1d ago
NASDAQ.COM
AstraZeneca's Imfinzi Approved by FDA for Bladder Cancer
1d ago
seekingalpha
AstraZeneca's Breast Cancer Therapy Review Delayed by FDA
3d ago
seekingalpha
AstraZeneca's Camizestrant NDA Review Date Extended by FDA
3d ago
NASDAQ.COM
AstraZeneca's New Drug Application Review Delayed by FDA
3d ago
NASDAQ.COM
AstraZeneca and Daiichi Sankyo's Datroway Approved by FDA for Breast Cancer Treatment
May 22 2026
seekingalpha
AstraZeneca and Daiichi Sankyo Launch Datroway for TNBC Treatment
May 22 2026
NASDAQ.COM
EU Drug Regulator Panel Endorses Eight New Medicines for Approval
May 22 2026
seekingalpha
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
DATROWAY Approved for Treatment of Triple-Negative Breast Cancer
May 22 2026
Newsfilter
Datroway Approved for Triple-Negative Breast Cancer Treatment
May 22 2026
Newsfilter
Enhertu Recommended for EU Approval as HER2 Targeted Therapy
May 22 2026
Newsfilter
Volatility in UK Assets Amid Political Turmoil and Investment Opportunities
May 21 2026
CNBC
Analysis of Trends in International Stock ETF Investments
May 19 2026
Fool
Show More News
